These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 3901446

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antithymocyte globulin therapy after renal transplantation at the Massachusetts General Hospital.
    Delmonico FL.
    Transplant Proc; 1984 Aug; 16(4):979-82. PubMed ID: 6380062
    [No Abstract] [Full Text] [Related]

  • 3. Individualized monitoring and modulation of immune reactivity using standardized antithymocyte globulin (ATG).
    Thomas F, Mendez-Picon G, Thomas J, Lee HM.
    Transplant Proc; 1979 Jun; 11(2):1429-30. PubMed ID: 382531
    [No Abstract] [Full Text] [Related]

  • 4. Antithymocyte globulin in cadaver renal grafts: prophylaxis and antirejection therapy with three different preparations.
    MacDonald AS, Belitsky P, Lannon SG, Cohen A, White J.
    Transplant Proc; 1982 Dec; 14(4):631-4. PubMed ID: 6762719
    [Abstract] [Full Text] [Related]

  • 5. Treatment of acute rejection of renal allografts with antithymocyte globulin or high-dosage prednisone. Influence of recipient DRw6 and DR matching.
    Hoitsma AJ, Van Lier HJ, Reekers P, Koene RA.
    Neth J Med; 1985 Dec; 28(6):239-42. PubMed ID: 3892324
    [No Abstract] [Full Text] [Related]

  • 6. The use of antilymphoblast globulin in the treatment of renal allograft rejection.
    Howard RJ, Condie RM, Sutherland DE, Simmons RL, Najarian JS.
    Transplant Proc; 1981 Mar; 13(1 Pt 1):473-4. PubMed ID: 7022876
    [No Abstract] [Full Text] [Related]

  • 7. Antithymocyte globulin (ATG) dosage and graft survival in renal transplantation.
    Kountz SL, Butt KH, Rao TK, Zielinski CM, Rafi M, Schultz JR.
    Transplant Proc; 1977 Mar; 9(1):1023-5. PubMed ID: 325728
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Superior renal allograft survival and decreased rejection with early high-dose and sequential multi-species antilymphocyte globulin therapy.
    Thomas F, Cunningham P, Thomas J, Gross U, Gaskins D, Sash C, Parker K.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1874-8. PubMed ID: 3547892
    [No Abstract] [Full Text] [Related]

  • 13. Sequential Minnesota antilymphoblast globulin and cyclosporine therapy after cadaver renal transplantation.
    Ludwin D, White N, Tsai S, Smith EK.
    Transplant Proc; 1985 Aug; 17(4):1943-4. PubMed ID: 3895635
    [No Abstract] [Full Text] [Related]

  • 14. Use of antithymocyte globulin for reversal of acute allograft rejection.
    Shield CF, Cosimi AB, Tolkoff-Rubin N, Rubin RH, Herrin J, Russell PS.
    Transplantation; 1979 Dec; 28(6):461-4. PubMed ID: 390784
    [No Abstract] [Full Text] [Related]

  • 15. Clinical uses of anti-thymocyte globulin (ATGAM), Part I.
    Gilbert C.
    N C Med J; 1984 Nov; 45(11):737-9. PubMed ID: 6392893
    [No Abstract] [Full Text] [Related]

  • 16. Multicenter comparison of rejection reversal: rabbit anti-human lymphocyte serum (ATS) versus horse anti-human lymphocyte globulin (ATGAM).
    Johnson K, Niblack G, Richie R, MacDonell R, Nylander W, Walker P, Sterling W, Ross G, Humphries A, Peterson D.
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1734-5. PubMed ID: 2652567
    [No Abstract] [Full Text] [Related]

  • 17. Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin.
    Cantarovich D, Le Mauff B, Hourmant M, Giral M, Denis M, Jacques Y, Soulillou JP.
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1769-71. PubMed ID: 2652579
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
    Alamartine E, Bellakoul R, Berthoux F.
    Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
    [No Abstract] [Full Text] [Related]

  • 20. Induction therapy with antithymocyte globulin reduces the incidence of allograft rejection and improves graft survival in cadaver renal transplantation.
    Abouna GM, Kumar MS, Stephan R, Prior JE, Lyons P, Bulova SI, al-Abdullah IH.
    Transplant Proc; 1993 Jun; 25(3):2241-2. PubMed ID: 8516886
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.